Filed with ASX · · 2 pages · English
The decision comes after reports of mild to moderate skin irritation in some participants, prompting a thorough review of the data before deciding on the future of the study. CEO Gary Phillips emphasized the importance of analyzing the collected data to inform the next steps in the trial process.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Media Release 10 November 2026 Syntara pauses recruitment in SNT-9465 Phase 1b skin scarring study Syntara Limited (ASX: SNT), a clinical-stage drug development company, today announces that it has paused recruitment of the Phase 1b study of its topical pan- lysyl oxidase inhibitor, SNT-9465, in...
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara